MedTrace Logo

Iranian Intensive Care Unit (ICU) Glutamine Study

NCT01219608 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-06-14

No results posted yet for this study

Summary

This is a double-blinded placebo-controlled block randomized study in intensive care patients comparing enteral glutamine supplementation to placebo. The hypothesis is an improvement of clinical and paraclinical outcomes. The primary endpoint is Infection Probability Score (IPS) and Systemic Inflammatory Response Syndrome (SIRS). Anthropometric measures and serum inflammatory mediators will be compared.

Conditions

  • Trauma Patients in ICU

Interventions

DIETARY_SUPPLEMENT

Glutamine 0.5 g/kg/day

Glutamine 0.5 g/kg/day

DIETARY_SUPPLEMENT

Glutamine 1 g/kg/day

Glutamine 1 g/kg/day

DIETARY_SUPPLEMENT

Enteral Nutrition

Ordinary Enteral Nutrition

Sponsors & Collaborators

  • Isfahan University of Medical Sciences

    collaborator OTHER

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01219608 on ClinicalTrials.gov